Serum Tumor Markers in Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia
Serum Tumor Markers in Non-Hodgkin's Lymphomas and Chronic Lymphocytic Leukemia
复制标题
非霍奇金淋巴瘤和慢性淋巴细胞白血病的血清肿瘤标志物
DOI：
10.1177/172460089300800103
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
A. Mavridis
中科院分区：
文献类型：
--
作者：
A. Pavlidis;J. Kalef;L.C. Bourantas;A. Lambrou;A. Mavridis
研究人员测量了 50 名既往未经治疗的非霍奇金淋巴瘤 (NHL) 和慢性淋巴细胞白血病 (CLL) 患者以及 25 名年龄和性别匹配的正常对照者血清中可溶性白细胞介素 2 受体 (sIL-2R)、β-2 微球蛋白 (β-2M)、红细胞沉降率 (ESR) 和 C 反应蛋白 (CRP) 的水平。与正常对照相比，NHL 和 CLL 中 sIL-2R 和 β-2M 的平均血清水平均显着升高（p < 0.001），而 ESR 和 CRP 的升高则不太明显（分别为 p < 0.01 和 p < 0.05）。这些肿瘤标志物与组织学分级的比较显示，低度、中度和高度恶性淋巴瘤之间仅 CRP 存在统计学显着差异（p < 0.001 和 p < 0.05）。较晚期阶段，所有血清标志物的平均值均高于早期阶段（sIL-2R、β-2M 和 ESR 的 p < 0.001，CRP 的 p < 0.05）。仅观察到 sIL-2R 与 b 症状存在相关性 (p < 0.05)。此外，sIL-2R 和 β-2M 能够预测弥漫性大细胞淋巴瘤患者的进展时间。我们得出的结论是，在测试的四种肿瘤标志物中，sIL-2R 和 β-2M 更频繁地表现出血清水平升高，并且与临床分期和/或 b 症状的存在相关。 sIL-2R 和 β-2M 也被发现对生存具有预后意义。
The levels of soluble interleukin-2 receptors (sIL-2R), beta-2 microglobulin (β-2M), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured in the serum of 50 previously untreated patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) as well as in 25 age and sex-matched normal controls. Compared to normal controls, mean serum levels of sIL-2R and β-2M were significantly increased in both NHL and CLL (p < 0.001) while the increase in ESR and CRP was less marked (p < 0.01 and p < 0.05, respectively). Comparison of these tumor markers with histologic grading showed statistically significant differences only for CRP between low, intermediate and high-grade lymphomas (p < 0.001 and p < 0.05). More advanced stages exhibited higher mean values of all serum markers than early stages (p < 0.001 for sIL-2R, β-2M and ESR and p < 0.05 for CRP). An association with the presence of b-symptoms was observed only for sIL-2R (p < 0.05). In addition, sIL-2R as well as β-2M were able to predict time to progression in patients with diffuse large-cell lymphomas. We conclude that of the four tumor markers tested sIL-2R and β-2M more frequently showed increased serum levels and were associated with clinical stage and/or presence of b-symptoms. Both sIL-2R and β-2M were also found to have prognostic significance for survival.